Insight Molecular Diagnostics (IMDX) Q4 2024 earnings summary

Executive summary

• Launched GraftAssure, a research-use-only kidney transplant test, with leading global transplant centers and incorporated feedback to improve assay design and user experience.

• Achieved key milestones including NEJM publication, Medicare reimbursement for VitaGraft Kidney, and FDA breakthrough designation for a partner drug, expanding the addressable market.

• Attracted Bio-Rad Laboratories as a strategic partner and investor, with Bio-Rad participating in all equity funding rounds and holding 9.66% of shares.

• Strengthened leadership team with a new CFO and Consulting Chief Medical Officer, and held a positive pre-submission meeting with the FDA.

• Fully funded clinical kitted product development with over $50M in equity raises and streamlined capital structure by redeeming Series A preferred stock.

Financial highlights

• Q4 2024 revenue was $1.5M, up from $0.31M in Q4 2023, with a 40% gross margin; full-year 2024 revenue was $1.9M.

• Q4 2024 gross profit was $595K (40% margin); full-year gross profit was $740K (39% margin).

• Q4 2024 operating expenses were $34.2M, including a $41.9M non-cash impairment loss and $13.7M non-cash gain from contingent consideration.

• Net loss for Q4 2024 was $33.5M; non-GAAP loss from operations was $4.4M.

• Year-end cash was $10.3M, excluding $29.1M raised in Feb 2025; cash and cash equivalents at year-end 2024 were $8.6M.

Outlook and guidance

• Targeting FDA submission for kitted transplant assay by end of 2025, with authorization expected in 2026 and major revenue growth in 2027.

• Aims to have at least 20 transplant centers signed by end of 2025, representing potential high-margin recurring revenue post-approval.

• Expects further validation data, commercial expansion, and broader industry shift to decentralized diagnostics by 2028.

• Cash burn targeted at $6M per quarter in 2025, with Q2 and Q3 expected to be the heaviest expense periods.

• Anticipates continued, but lower, pharma services revenue in the first half of 2025 as focus shifts to FDA submission.